Trial BMS CA209-9KD

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial

Trial acronym

BMS CA209-9KD

Full title

A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or
Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer (CheckMate 9KD:
CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9KD)

Responsible organization

Urologie MRI Ismaninger Str.22 81675 München Germany

Indications

Classification	Code	Description
-		Prostatecancer

Trial design

Phase

Status

Recruitment finished

Votes

Initiiation & lock

Date of lock (planned / actual)

Unknown / Unknown

Therapy

Chemo,Zielgerichtet

Participants

	Function	Prename	Surname	Organization
	Responsible contact			Urologie MRI Ismaninger Str.22 81675 München Germany